Squarepoint Ops LLC Biocryst Pharmaceuticals Inc Transaction History

Squarepoint Ops LLC

$96.1 Billion
Q3 2025

A detailed history of Squarepoint Ops LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Squarepoint Ops LLC holds 1,108,660 shares of BCRX stock, worth $7.85 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,108,660

Previous 723,321 53.27%

Holding current value

$7.85 Million

Previous $6.48 Million 29.85%

% of portfolio

0.01%

Previous 0.01%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$7.55 - $9.06 $2.91 Million - $3.49 Million	385,339 Added 53.27%	1,108,660 $8.41 Million
Q2 2025 Aug 27, 2025	SELL	$6.41 - $11.19 $266,508 - $465,246	-41,577 Reduced 5.44%	723,321 $6.48 Million
Q2 2025 Aug 14, 2025	SELL	$6.41 - $11.19 $266,508 - $465,246	-41,577 Reduced 5.44%	723,321 $6.48 Million
Q1 2025 Aug 27, 2025	BUY	$7.06 - $9.39 $293,533 - $390,408	41,577 Added 5.75%	764,898 $5.74 Million
Q1 2025 May 15, 2025	BUY	$7.06 - $9.39 $2.86 Million - $3.8 Million	405,017 Added 112.54%	764,898 $5.74 Million
Q4 2024 Feb 14, 2025	BUY	$7.03 - $8.43 $2.43 Million - $2.91 Million	345,729 Added 2442.97%	359,881 $2.71 Million
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $90,714 - $122,980	14,152 New	14,152 $107,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $1.09 Million - $1.71 Million	-223,060 Reduced 69.56%	97,614 $495,000
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $1.5 Million - $2.04 Million	300,950 Added 1525.81%	320,674 $1.92 Million
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $912,114 - $1.15 Million	-131,051 Reduced 86.92%	19,724 $138,000
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $1.01 Million - $1.5 Million	-126,966 Reduced 45.71%	150,775 $1.26 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $1.09 Million - $1.47 Million	103,574 Added 59.47%	277,741 $3.19 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $1.88 Million - $2.58 Million	174,167 New	174,167 $2.2 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $2.39 Million - $5.42 Million	-303,008 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $2.94 Million - $5.03 Million	254,642 Added 526.49%	303,008 $4.93 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $540,731 - $747,738	48,366 New	48,366 $670,000
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $539,315 - $978,714	-56,770 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $255,112 - $471,110	34,615 Added 156.24%	56,770 $577,000
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $36,244 - $92,600	10,755 Added 94.34%	22,155 $165,000
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $252,351 - $406,853	-73,572 Reduced 86.58%	11,400 $39,000
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $4,941 - $14,591	-2,601 Reduced 2.97%	84,972 $405,000
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $850,192 - $2.18 Million	-531,370 Reduced 85.85%	87,573 $175,000
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $417,409 - $905,700	262,522 Added 73.66%	618,943 $2.14 Million
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $783,270 - $1.17 Million	313,308 Added 726.71%	356,421 $1.02 Million
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $201,174 - $632,557	-69,132 Reduced 61.59%	43,113 $163,000
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $480,105 - $632,334	65,055 Added 137.86%	112,245 $914,000
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $87,370 - $128,841	-13,421 Reduced 22.14%	47,190 $381,000
Q3 2018 Nov 14, 2018	SELL	$5.52 - $7.99 $359,368 - $520,172	-65,103 Reduced 51.79%	60,611 $462,000
Q2 2018 Aug 14, 2018	BUY	$4.6 - $6.52 $578,284 - $819,655	125,714 New	125,714 $720,000
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $272,018 - $348,523	-65,389 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $268,094 - $390,372	65,389	65,389 $343,000

Others Institutions Holding BCRX

# of Institutions

311

Shares Held

200M

Call Options Held

640K

Put Options Held

507K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.32B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC Biocryst Pharmaceuticals Inc Transaction History